VMD Stock Overview
Engages in the pharmaceutical distribution business. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Vimedimex Medi-Pharma Joint Stock Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₫16,650.00 |
| 52 Week High | ₫21,200.00 |
| 52 Week Low | ₫16,050.00 |
| Beta | 0 |
| 1 Month Change | -15.91% |
| 3 Month Change | -10.00% |
| 1 Year Change | -2.06% |
| 3 Year Change | -53.10% |
| 5 Year Change | -32.32% |
| Change since IPO | -47.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| VMD | VN Healthcare | VN Market | |
|---|---|---|---|
| 7D | -1.2% | -0.4% | 1.6% |
| 1Y | -2.1% | -4.9% | 11.4% |
Return vs Industry: VMD exceeded the VN Healthcare industry which returned -4.9% over the past year.
Return vs Market: VMD underperformed the VN Market which returned 11.4% over the past year.
Price Volatility
| VMD volatility | |
|---|---|
| VMD Average Weekly Movement | 4.3% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in VN Market | 7.0% |
| 10% least volatile stocks in VN Market | 2.0% |
Stable Share Price: VMD has not had significant price volatility in the past 3 months compared to the VN market.
Volatility Over Time: VMD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Pham Sen | vietpharm.com.vn |
Vimedimex Medi-Pharma Joint Stock Company engages in the pharmaceutical distribution business. The company also produces medicines. In addition, it offers imported drugs, domestic medicines, functional food, family medical equipment, and mother and baby consumer goods.
Vimedimex Medi-Pharma Joint Stock Company Fundamentals Summary
| VMD fundamental statistics | |
|---|---|
| Market cap | ₫257.08b |
| Earnings (TTM) | ₫0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs VMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VMD income statement (TTM) | |
|---|---|
| Revenue | ₫0 |
| Cost of Revenue | ₫0 |
| Gross Profit | ₫0 |
| Other Expenses | ₫0 |
| Earnings | ₫0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did VMD perform over the long term?
See historical performance and comparisonDividends
12.0%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 17:54 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vimedimex Medi-Pharma Joint Stock Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|